-

Jennifer Schneider Elected to Vertex Board of Directors

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Jennifer Schneider, M.D., M.S., has been elected to its Board of Directors as an independent director. Dr. Schneider has more than two decades of experience in the health care industry as a physician, scientist and health care executive. She co-founded and serves as Chief Executive Officer of Homeward Health, a company committed to rearchitecting the delivery of health and care for nearly 60 million Americans living in rural America. Prior to founding Homeward in 2022, Dr. Schneider served as President and Chief Medical Officer of Livongo Health, a biotechnology company serving people with chronic conditions including diabetes, hypertension, obesity and behavioral health issues. While there, she led the company through the largest consumer digital health Initial Public Offering in history and the industry’s largest merger between Livongo and Teladoc Health. She also served as Chief Medical Officer of Castlight Health, a health care navigation company for self-insured companies.

“We’re thrilled to have Jenny join the Vertex Board. She brings a unique perspective and experience as a physician-executive with deep expertise in health systems, policy and reimbursement, as well as technology-enabled health care. As Vertex enters a new era of commercial diversification, Jenny’s decades-long work in population health and reimbursement, her data and analytical skills, and ability to apply emerging health technologies to complex problems will help Vertex fulfill its mission to serve more patients across new diseases and therapeutic modalities,” said Jeffrey Leiden, M.D., Ph.D., Executive Chairman of Vertex.

“I am honored to join the Vertex Board at this incredibly exciting time in the company’s history with its commitment to innovation yielding extraordinary achievements in cystic fibrosis, sickle cell disease, and beta thalassemia, among others,” said Jennifer Schneider, M.D., M.S. “I look forward to working with my fellow directors to support the company’s continued innovation and growth.”

Prior to her industry roles, Dr. Schneider conducted research in health services at Stanford University and worked as a physician in internal medicine at various hospitals. She currently serves on the Board of Directors of Jasper Health and Maven Health. Dr. Schneider holds a Bachelor of Arts in biology from the College of the Holy Cross, a Doctorate in Medicine from Johns Hopkins University School of Medicine, and a Master of Science in health services research from Stanford University.

The addition of Dr. Schneider brings Vertex’s board of directors to 11 members, nine of whom are independent and 45% of whom are women.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including APOL1-mediated kidney disease, acute and neuropathic pain, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency.

Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 14 consecutive years on Science magazine's Top Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit www.vrtx.com or follow us on LinkedIn, Facebook, Instagram, YouTube and Twitter/X.

(VRTX-GEN)

Contacts

Vertex Pharmaceuticals Incorporated
Investors:
InvestorInfo@vrtx.com
Susie Lisa, CFA: +1 617-341-6108
or
Manisha Pai: +1 617-961-1899
or
Miroslava Minkova: +1 617-341-6135

Media:
mediainfo@vrtx.com
or
U.S.: +1 617-341-6992
or
Heather Nichols: +1 617-839-3607

Vertex Pharmaceuticals Incorporated

NASDAQ:VRTX

Release Versions

Contacts

Vertex Pharmaceuticals Incorporated
Investors:
InvestorInfo@vrtx.com
Susie Lisa, CFA: +1 617-341-6108
or
Manisha Pai: +1 617-961-1899
or
Miroslava Minkova: +1 617-341-6135

Media:
mediainfo@vrtx.com
or
U.S.: +1 617-341-6992
or
Heather Nichols: +1 617-839-3607

More News From Vertex Pharmaceuticals Incorporated

Vertex to Announce Second Quarter 2026 Financial Results on August 3rd

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2026 financial results on Monday, August 3, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the “Vertex Pharmaceuticals Second Quarter 2026 Earnings Call.” The conference call will be webcast live and a link to the webcast ca...

Vertex to Acquire Crinetics Pharmaceuticals

BOSTON & SAN DIEGO--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10.0 billion, or approximately...

Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved expanded use of CASGEVY® (exagamglogene autotemcel) for the treatment of people ages 2 years and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first approved genetic therapy indicated for children as young as 2 years for both SCD and TDT....
Back to Newsroom